Anzeige
Mehr »
Login
Montag, 27.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
US-Präsident setzt auf die Solana Blockchain! Diese Krypto-Perle profitiert enorm!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
536 Leser
Artikel bewerten:
(2)

KR1 plc - Appointment of Non-executive Director

Finanznachrichten News

KR1 plc - Appointment of Non-executive Director

PR Newswire

17 March 2020

KR1 PLC

("KR1" or the "Company")

Appointment of Non-executive Director

KR1 plc (KR1:AQSE), a leading digital asset investment company, is pleased to announce that Mona Elisa has been appointed as a Non-executive Director of the Company with effect from today.

Mona is the CEO of Avantgarde Finance and was formerly the co-founder and CEO of Melonport AG, which developed Enzyme (formerly Melon), an Ethereum-based protocol for decentralised on-chain asset management. Mona Elisa is a former star-trader at Goldman Sachs, promoted to Vice President by the age of 26 and made the "Top 30 Under 30" list in Trader Magazine in 2008 and Forbes Magazine in 2011 after profitably trading the 2008 and 2011 crashes. After that, she moved to Geneva-based macro hedge fund Jabre Capital in 2011, before deciding in 2014 that the future of finance lay in blockchain technology. Mona studied Economics & Statistics at the University College London.

Mona has been granted options to subscribe for 77,519 ordinary shares of 0.19p each in the Company ("Ordinary Shares") at a price of 193.5p per share, being the closing share price on the day prior to her appointment. These options will only be exercisable in the event that certain future milestones are achieved by the Company.

Mona Elisa commented: "I am honoured and delighted to be joining the board. The KR1 team are pioneers in the crypto investment space and first discovered Enzyme (then, Melon) in 2016 before we were even looking to raise capital. KR1 offers much more than capital, they understand the challenges an entrepreneur faces and have been around long enough to prove that they are there for their portfolio companies during the ups and the downs. This unique combination of skills and experience sets them up as the best kind of investor and mentor a founder could ask for."

Keld van Schreven, Managing Director and Co-Founder of KR1, commented: "We are thrilled to appoint Mona. Enzyme (formerly Melon) was the Company's first major investment and, since then, we have shared an incredibly successful journey together. Having been a star in traditional finance early in her career, Mona brings a lot of experience and an extensive network in the blockchain world to the table. Her energy and experience will be highly welcome and appreciated going forward."

The Directors of KR1 plc accept responsibility for this announcement.

--ENDS--

For further information please contact:

KR1 PLC
George McDonaugh
Keld van Schreven
Simon Nicol

+44 (0)16 2467 6716

simon@KR1.io
Peterhouse Capital Limited
Mark Anwyl
Allie Feuerlein
(AQSE Corporate Adviser)
+44 (0)20 7469 0930
Nominis Advisory Ltd
Angus Campbell
(PR Adviser)
pr@KR1.io

Save as set out below, there is no further information regarding Mona Elisa that is required to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Apex Rulebook.

Current Directorships/PartnershipsPast Directorships/Partnerships
Avantgarde CoreMelonport AG
Avantgarde Finance Ltd
Midas Technologies AG
Near Foundation AG
Multichain Asset Managers Association (MAMA)

About KR1 plc

KR1 is a leading digital asset investment company supporting early-stage decentralised and open source blockchain and DeFi projects. Founded in 2016 and publicly traded in London on the Apex segment of the AQSE Growth Market (KR1: AQSE), KR1 has built a notable reputation for generating significant returns by investing in many key projects that are designed to power the decentralised platforms and protocols that are emerging to form new internet infrastructures.

www.KR1.io

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1Details of the person discharging managerial responsibilities / person closely associated
a)NameMona Elisa
2Reason for the notification
a)Position/statusNon-Executive Director
b)Initial notification /AmendmentInitial
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameKR1 Plc
b)LEI213800WFTIIBY5SBCL19
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument
Identification code

Ordinary shares of 0.19 pence each

ISIN: IM00BYYPQX37
b)Nature of the transactionGrant of Options
c)Price(s) and volume(s)77,519 Ordinary Shares at 193.5p per share
d)Aggregated information
- Aggregated volume
- Price


N/A
e)Date of the transaction16 March 2020
f)Place of the transactionNot a market transaction
© 2021 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.